The association of adiponectin and dyslipidemias is based on the fact that adiponectin exhibits its effects through the sensitivity of the body to insulin and the oxidation of fatty acids [58, 59] via the activation of several signaling molecules including adenosine monophosphate-activated protein kinase, p38-MAPK, JNK, the PPARγ transcription factor, and NF-ƙβ in various tissues. Here, ADIPOQ is linked to metabolic syndrome.